| Ouleiqiang |
Mr. Ou Leiqiang is the founder, chairman and CEO of Baekje China. He has also served on the Board of Directors since 2010. Previously, Mr. Ou Leiqiang served as the president and CEO of Bono Technology, a pharmaceutical R&D outsourcing company, from 2005 to 2009. The company was acquired by Pharmaceutical Product Development Inc. in 2010. From 2002 to 2004, Mr. Ou Leiqiang served as the CEO of Galenea, a biopharmaceutical company founded in Massachusetts Institute of Technology, focusing on the research and development of innovative therapies for central nervous system diseases. From 1997 to 2002, Mr. Ou Leiqiang founded Telephia Company and served as its president, which was acquired by Nielsen Company in 2007. From 1997 to 1998, Mr. Ou Leiqiang served as the co CEO of Genta Company (NASDAQ code: GNTA), a biomedical enterprise focusing on tumor. Mr. Ou Leiqiang started his career as a business consultant of McKinsey&Company in the United States. Mr. Ou Leiqiang holds an MBA from Stanford University and a bachelor's degree from Massachusetts Institute of Technology. |
| Wu Xiaobin |
Dr. Wu Xiaobin joined Baekje in 2018 and served as the general manager of China and president of the company. Previously, Dr. Wu Xiaobin served as the country manager of Pfizer China from October 2009 to April 2018, and also served as the president of Pfizer Core Medical Greater China. Under his leadership, Pfizer successfully expanded its product line and organizational structure, significantly increased its sales, and launched a series of innovative marketing projects, thus establishing its leading position in the Chinese market as a multinational pharmaceutical company. Before joining Pfizer, Dr. Wu Xiaobin served as the president and general manager of Wyeth Pharmaceuticals in China and Hong Kong from August 2004 to October 2009. Before joining Wyeth, he was the general manager of Bayer Healthcare Co., Ltd. (China) from 2001 to 2004. Dr. Wu Xiaobin joined the sales and marketing department of Bayer in Germany in 1992, and has started his career since then. Dr. Wu Xiaobin holds a doctor's degree in biochemistry and pharmacology and a master's degree in molecular biology from the University of Konstanz, Germany. |
| Wang Xiaodong |
Dr. Wang Xiaodong, the founder of Baekje China, has served as the chairman of the Scientific Advisory Committee of the Company since 2011 and became a member of the Board of Directors of the Company in February 2016. He became the first co director and senior researcher of Beijing Institute of Life Sciences in 2003, and was appointed director in 2010. Previously, Dr. Wang Xiaodong was a researcher at Howard Hughes Medical Research Institute from 1997 to 2010, and an outstanding chief professor of biomedical science at the Southwest Medical Center of the University of Texas from 2001 to 2010. In 2004, with the support of venture capital, Dr. Wang Xiaodong founded Joyant Pharmaceuticals, a biotechnology company focusing on small molecule cancer therapy. Dr. Wang Xiaodong holds a doctorate in biochemistry from the University of Texas Southwestern Medical Center and a bachelor's degree from the Department of Biology, Beijing Normal University. Dr. Wang Xiaodong was elected an academician of the National Academy of Sciences in 2004 and a foreign academician of the Chinese Academy of Sciences in 2013. |
| Donald W. Glazer |
Donald W. Glazer has been a member of the Board of Directors since February 2013. Donald W. Glazer has served on the Board of Directors of GMO Trust, a mutual fund group, since 2000, and as Chairman of the Board of Directors of GMO Trust since 2005. Donald W. Glazer is the co-founder and secretary of Provant, Inc., a provider of performance improvement training solutions, and served as the vice chairman from 2002 to 2010. From 1992 to 1995, Donald W. Glazer served as the president of Muga/Glazer Holding Company, vice chairman from 1992 to 1993, and since 1997, Donald W. Glazer has served as the financial adviser of New England Television Corp. and WHDH-TV, Inc., and served as the adviser of Goodwin Procter LLP Law Firm. Donald W. Glazer was a partner from 1970 to 1978. From 1978 to 1992, he was a partner of the Law Firm of Ropes&Gray. At Lopez&Gray, Donald W. Glazer is the chairman of the company's emerging companies group. From 1978 to 1991, Donald W. Glazer was also a law lecturer at Harvard Law School, teaching a course called Commercial Lawyer. In addition to Provant, Inc. and New England Television, Donald W. Glazer is a former member of the board of directors of Environment Inc; Kronos; Reflex Technologies; In June 1966, Mr. Telecom Oilfield Services Inc. Glazer received his bachelor's degree from Dartmouth College; Graduated from Harvard Law School in June 1969, editor of Harvard Law Review; In May 1970, L L.M。 In addition, Donald W. Glazer is a co-author of Glazer and FitzGibbon on Legal Opinions (the third edition) (Aspen Publishers) and Massachusetts Corporation Law&Practice (the second edition) (Aspen Publishers). We believe that Donald W. Glazer's qualifications on the Board of Directors include his extensive experience in leadership, execution, management, business and corporate law. |
| Olivier Brandicourt |
Dr. Brandicourt is currently a senior consultant of Blackstone Life Sciences, the private equity department of Blackstone Group, which invests in the field of life science. He joined Blackstone Life Sciences in 2019. He is currently a member of the board of directors of Alnylam Pharmaceuticals, Inc. (a commercial stage biopharmaceutical company listed on NASDAQ, developing new RNAi based therapies); BenevolentAI S.A., A clinical AI drug research and development company listed on the Pan European Exchange; And privately held condensate biotechnology company Dew Point Treatment Company. He also serves as the chairman of the board of directors of AvenCell Therapeutics, Inc. AvenCell Therapeutics is a privately held leading clinical stage cell therapy company focused on promoting switchable and alloengineered CAR-T cell therapy. He has more than 30 years of experience in the global pharmaceutical industry, including serving as a senior leader of three global pharmaceutical companies. From April 2015 to August 2019, he served as chief executive officer and board member of Sanofi S.A. Prior to Sanofi, he served as CEO and Chairman of Bayer HealthCare AG (November 2013 to March 2015). From 2000 to 2013, he held various operational and management positions at Pfizer Inc., including serving as a member of the executive leadership team, president and general manager of the emerging markets and mature product business units. During his tenure at Sanofi, Dr. Brandicourt was elected chairman of the U.S. Drug Research and Manufacturers Regulatory Commission in 2019, and served as vice chairman of the European Federation of Pharmaceutical Industries and Associations from 2017 to 2019. He is an honorary member of the Royal College of Internal Medicine in London. Dr. Brandicourt studied medicine in Paris, specializing in infectious diseases and tropical medicine, and holds a master's degree in biology from the 12th University of Paris and an advanced degree in cell and immunopathophysiology from the University of Descartes in Paris. |
| Alessandro Riva |
Alessandro Riva is currently the CEO of Endometrial Biosciences, a privately held clinical stage gene and cell therapy company. From 2019 to 2021, he served as the CEO of the privately held Ichnos Sciences Inc., where he established a biotechnology company focusing on bispecific and trispecific antibodies in oncology and biological agents in autoimmune diseases. From 2017 to 2019, he served as executive vice president of Gilead Sciences and global director of tumor therapeutics and cell and gene therapy, where he helped to acquire Kite Pharma. Before joining Gilead, from 2005 to 2016, Dr. Riva served as the executive vice president and global director of tumor development and medical affairs of Novartis Pharmaceuticals, where he made significant contributions to the tumor business department and gene therapy department. During the acquisition of GSK Oncology, he also served as the interim president of Novartis Oncology. Dr. Riva is currently a member of the board of directors of Century Therapeutics, Inc., a biotechnology company listed on NASDAQ, which develops innovative ipsc derived NK and T cell therapies. He once held positions in Farmitalia Carlo Erba, Rh ô ne Poulenc Rorer and Aventis, and co founded the Breast Cancer International Research Group (BCIRG) and Cancer International Research Group (CIRG), where he served as CEO. He received doctor's degrees in medicine and surgery from the University of Milan, and obtained certificates in oncology and hematology from the same institution. |
| Margaret Dugan |
Margaret Dugan is currently the chief medical officer of Dracen Pharmaceuticals, Inc., a private pharmaceutical company headquartered in New York, which uses immune mediation in oncology. She joined Tecan in 2018 and has more than 20 years of experience in oncology. From 1998 to 2018, Margaret Dugan held senior leadership positions in Novartis Oncology, including senior vice president and global project leader, to develop innovative drugs for patients. Prior to this, Margaret Dugan held several development positions at Schering Plough (now Merck) and Cyanamide (now Pfizer). Margaret Dugan received a bachelor's degree in art and medicine from New York University, and received training in hematology and oncology. |
| Ranjeev Krishana |
Ranjeev Krishana has served as the director of Baekje Shenzhou Co., Ltd. since October 2014; He has worked at Baker Bros. Advisors LP since 2011; Currently, he is the head of international investment. Before joining Baker Brothers, he held a series of leading positions in business, strategy and business development in many international regions and markets such as Asia, Eastern Europe and Latin America of Pfizer Pharmaceutical. He served at Pfizer from 2003 to 2007 and from 2008 to 2011. From 2008 to 2010, he mainly worked in Beijing as a senior manager of Pfizer and a member of the Chinese leadership team. He started his career as a strategic consultant at Accenture plc. He received a double bachelor's degree in economics and political science from Brown University and a master's degree in public policy from Harvard University. |
| Michael Goller |
Mr. Michael Goller has served on the Board of Directors since April 2015. Mr. Goller is a partner of Baker Brothers Investments. Before joining Baker Brothers in 2005, Mr. Goller was a partner of JPMorgan Partners Limited. From 1999 to 2003, he focused on venture capital in the field of life science. Goller started his career as an investment banker at Merrill Lynch from 1997 to 1999. Mr. Goller received his bachelor's degree in molecular and cell biology from Pennsylvania State University in May 1997, and his master's degree in biotechnology (School of Engineering and Applied Sciences) and business administration (Wharton School of Business) from the University of Pennsylvania in May 2005. Mr. Goller is a member of the Board of Directors of DBV Technologies SA, which is listed on NASDAQ, Euronext Paris and Levo Therapeutics, Inc. |
| Yi Nuoqing |
Yi Nuoqing has been a member of the Board of Directors since October 2014. At the beginning of the establishment of Hillhouse Capital Group in 2005, Mr. Yi joined the group and later became a partner. Before working at Hillhouse Capital, Mr. Yi was a former stock market research analyst of China International Finance Corporation. In Hillhouse Capital, Mr. Yi is mainly engaged in public offering and private investment portfolio in the medical and consumer fields. He holds a Bachelor of Science degree in engineering from Shanghai Maritime University and a Master of Business Administration from the University of Southern California. |
| Anthony C. Hooper |
Mr. Anthony C. Hooper has served on the Board of Directors since January 2020. Mr. Hooper retired from Amgen in January 2020, served as Executive Vice President from September 2018 to January 2020, and served as Executive Vice President of Global Commercial Operations from 2011 to August 2018. From 2010 to 2011, he served as Senior Vice President of Commercial Operations of Bristol Myers Squibb Company (BMS), President of the United States, Japan and Intercontinental. From 2009 to 2010, he served as President of BMS Americas. From 2004 to 2009, he was the president of U.S. Pharmaceuticals, a division of BMS, the Worldwide Pharmaceuticals Group. Prior to that, he held various senior leadership positions at BMS. Prior to joining BMS, he served as Assistant Vice President of Global Marketing at Wyeth Laboratories. Mr. Hooper received his master's degree in law and business administration from the University of South Africa in 1978 and 1988 respectively. He is a member of the board of directors of MannKind Corporation (NASDAQ listed company, stock code: MNKD). He is an adviser to Amgen. |
| Corazon (Corsee) D. Sanders |
Dr. Corazon (Corsee) D. Sanders has served as a member of the Board of Directors since August 2020. Dr. Sanders recently served as temporary transition consultant of Bristol Myers Squibb Global Development Group in November 2019, and acquired Celgene Corporation until February 2020. Previously, Dr. Sanders served as the strategic adviser of Celgene's Chief Medical Officer's Office from March 2018 to November 2019. From January 2017 to March 2018, she served as a member of the Juno Therapeutics Executive Committee and the executive vice president of development and operation, responsible for strategic operations, quantitative science, biological samples and clinical operations. From 1994 to 2017, Dr. Sanders held leadership positions in Genentech/Roche, including serving as a member of Genentech/Roche's late stage portfolio committee, the global head of Genentech/Roche's late stage clinical operations, the global head of Genentech/Roche Biometric Group and the head of Genentech's data (design, analysis, technology and management) before the acquisition of Roche. Dr. Sanders is currently a member of the board of directors of the Fred Hutchinson Cancer Research Center in Seattle, Washington, and a director of the following biotechnology companies: Molecular Templates Inc. (NASDAQ: MTEM), Legend Biotech Corporation (NASDAQ: LEGN) and AltruBio Inc. (formerly AbGenomics) (privately held). Dr. Sanders graduated with honors from the University of the Philippines with bachelor's and master's degrees in statistics, and obtained master's and doctor's degrees in statistics from the Wharton doctoral program of the University of Pennsylvania. |
| Chan Lee |
Chan Lee, General Counsel. |
| Wang Aijun |
Wang Aijun served as the Senior Vice President and Deputy Chief Financial Officer of the Company's Enterprise Optimization from June 2020 to June 2021. Prior to that, from 2018 to 2020, Wang Aijun served as senior vice president of global business finance and enterprise planning at Alexion Pharmaceuticals, a rare disease biopharmaceutical company with business in more than 50 countries. From 2015 to 2018, she held leadership positions in Quest Diagnostics, including vice president of finance and corporate commerce in the United States, and vice president of finance and value creation. From 2007 to 2012, she held a senior leadership position in J&J and served as the CFO of several operational businesses, including Xi'an Janssen, Johnson's pharmaceutical business in China. Before 2007, she was responsible for financial planning at PepsiCo. Wang Aijun received his MBA degree from Duke University's Fuku School of Business in 1999, and his bachelor's degree in English language and literature from Shandong Normal University in 1992. |
| Titus Ball |
Mr. Ball joined the company in August 2023 as Vice President and Chief Accounting Officer. Before joining the company, Mr. Ball served as the Managing Director of KPMG's accounting consulting business from 2022 to 2023. From 2010 to 2021, he held various financial positions in Carlisle Companies Inc., with increasing responsibilities, including recently serving as vice president of finance in the fluid technology department of Carlisle Companies Inc. and vice president and chief accounting officer of Carlisle Companies Inc. Prior to joining Carlisle Companies Inc., he was the senior audit manager of PricewaterhouseCoopers. He holds a bachelor's degree in economics and business administration from King University. |
| Mark Lanasa |
Mark Lanasa, Chief Medical Officer, Solid Tumors. |
| Lai Wang |
Dr. Lai Wang has been our Global Head of R&D since April 2021. Dr. Wang joined our company in May 2011, and his responsibilities have increased over the years. Recently, he served as Senior Vice President, Head of Global Research, Clinical Operations and Biometrics, and Asia Pacific Clinical Development. Dr. Wang has more than 20 years of experience in the field of cancer and more than 10 years of R&D experience in the pharmaceutical industry. Before joining us, Dr. Wang was the research director of Joyant Pharmaceuticals, a biotechnology company based in Dallas, Texas. Dr. Wang received his bachelor's degree from Fudan University in 1996 and his doctor's degree from the University of Texas Health Science Center in San Antonio in 2001. |
